KRAS and cancer: Indeed, research studies indicate that individuals with early‐stage cancers may host down to one mutated gene or protein per 0.1 mL of plasma, necessitating detection limits in the 10 zeptomolar, zM, range (10−20 M).[5, 6] Historically, mutated DNA genes, such as KRAS and TP53,[7, 8] released by cancer cells have been explored as suitable pancreatic cancer precursors biomarkers, relying on the capability of Polymerase Chain Reaction (PCR)[9] based assays and Next Generation Sequencing (NGS)[10] to track oncogenes down to the single copy in 0.1 mL (10 zM concentration).